Fetal Pulse Oximetry for Fetal Hypoxia
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new method to measure oxygen levels in unborn babies using a device placed on the mother's belly, known as Trans-abdominal Fetal Pulse Oximetry. The goal is to improve how doctors understand and monitor oxygen levels in babies still in the womb. The study involves short sessions where the device measures how light passes through the mother's and baby's tissues. Women who are at least 36 weeks pregnant with one healthy baby might be suitable candidates, especially if they can attend testing sessions outside regular hours. As an unphased trial, this study allows participants to contribute to innovative research that could enhance prenatal care.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that this fetal pulse oximetry is safe for use?
Research has shown that trans-abdominal fetal pulse oximetry is a safe and non-invasive method to monitor a baby's oxygen levels before birth. Studies have demonstrated that the Lumerah device, which uses this technology, does not harm the mother or baby. It checks the baby’s oxygen levels using light, avoiding the need for needles or other invasive tools.
The Gen 3 Monitoring device, which employs similar technology, has also been used safely in other studies to measure how light interacts with the mother's abdomen. No reports of serious side effects or harm have emerged from using these devices.
Overall, these devices are designed to be safe, providing a non-invasive way to monitor a baby's health before delivery.12345Why are researchers excited about this trial?
Researchers are excited about the new approach using GEN 3 Monitoring of Fetus and Trans-abdominal Fetal Pulse Oximetry for fetal hypoxia because it offers a non-invasive way to monitor fetal oxygen levels directly. Unlike the standard of care, which often relies on indirect methods like fetal heart rate monitoring, this technique measures light scattering and absorption to provide real-time data on oxygen saturation. This could lead to more accurate assessments and timely interventions, potentially improving outcomes for both mothers and babies.
What evidence suggests that this fetal pulse oximetry is effective for fetal hypoxia?
This trial will evaluate the effectiveness of trans-abdominal fetal pulse oximetry, specifically using the GEN 3 Monitoring of Fetus and the Lumerah System. Studies have shown that trans-abdominal fetal pulse oximetry accurately measures a baby's oxygen levels before birth. This technology uses a non-invasive method to determine if a baby receives enough oxygen, helping to identify potential problems early. Some research suggests it can enhance how doctors monitor a baby's health during labor and reduce unnecessary medical procedures. The device functions by shining light through the mother's abdomen to measure the baby's blood oxygen, similar to a finger pulse oximeter. These early findings suggest it could be a valuable tool in monitoring a baby's health.23456
Who Is on the Research Team?
Mark Rosen, MD
Principal Investigator
Raydiant Oximetry
Are You a Good Fit for This Trial?
This trial is for women over 18 years old with a single, healthy pregnancy at or beyond 36 weeks of gestation. Participants must be willing to come in for testing outside regular business hours, including Saturdays. It's not open to those with pregnancies less than 36 weeks, under the age of 18, or carrying multiples like twins.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Measurement
The Gen 3 device is positioned on the maternal abdomen to measure light scattering and absorption for a period of about 10-20 minutes, with a possible second measurement for a total of up to 40 minutes.
Follow-up
Participants are monitored for safety and effectiveness after the measurement phase
What Are the Treatments Tested in This Trial?
Interventions
- GEN 3 Monitoring of Fetus
- Trans-abdominal Fetal Pulse Oximetry
Find a Clinic Near You
Who Is Running the Clinical Trial?
Raydiant Oximetry, Inc.
Lead Sponsor